Better and safer cancer therapeutics first in line
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Update
LiPlasome Pharma welcomes Charlotte Vermehren as DMPK Manager
Charlotte Vermehren joined LiPlasome as DMPK...
LiPlasome Pharma welcomes Mogens Winkel Madsen as Chief Scientific Officer
Dr. Madsen has more than 20 years experience within drug discovery and cancer research...
Creating a successful business with a new visual identity
The upcoming biotech company LiPlasome Pharma A/S is launching a new visual identity...
Current Progress
LiPlasome Pharma has successfully concluded part of its preclinical studies and demonstrated proof of principle of the tumor activated and integrated prod...
